MENU
IMDX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

IMDX stock forecast, quote, news & analysis

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes... Show more

IMDX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IMDX with price predictions
Sep 11, 2026

IMDX sees its Stochastic Oscillator recovers from oversold territory

On September 03, 2026, the Stochastic Oscillator for IMDX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 74 instances where the indicator left the oversold zone. In 65 of the 74 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMDX's RSI Oscillator exited the oversold zone, 21 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for IMDX just turned positive on September 04, 2026. Looking at past instances where IMDX's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.

Following a +3.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMDX as a result. In 83 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (196.078) is normal, around the industry mean (60.137). P/E Ratio (0.000) is within average values for comparable stocks, (156.768). IMDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.504). IMDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). IMDX's P/S Ratio (85.470) is very high in comparison to the industry average of (9.865).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 18.5B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -4%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 36%. BNR experienced the highest price growth at 8%, while BIAF experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -17%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -59%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 61
Price Growth Rating: 42
SMR Rating: 78
Profit Risk Rating: 90
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
IMDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer

Industry MedicalSpecialties

Profile
Details
Industry
Medical Specialties
Address
2 International Plaza Drive
Phone
+1 615 255-8880
Employees
58
Web
https://www.imdxinc.com
IMDX sees its Stochastic Oscillator recovers from oversold territory